15d-PGJ\textsubscript{2} inhibits NF-κB and AP-1-mediated MMP-9 expression and invasion of breast cancer cell by means of a heme oxygenase-1-dependent mechanism

Hye-Yeon Jang\textsuperscript{1}, On-Yu Hong\textsuperscript{1}, Hyun Jo Youn\textsuperscript{2}, Min-Gul Kim\textsuperscript{3}, Cheorl-Ho Kim\textsuperscript{4}, Sung Hoo Jung\textsuperscript{2,*} & Jong-Suk Kim\textsuperscript{1,*}

\textsuperscript{1}Department of Biochemistry, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju 54907, \textsuperscript{2}Department of Surgery, Research Institute of Clinical Medicine, Chonbuk National University Hospital, Chonbuk National University and Biomedical Research Institute, Jeonju 54907, \textsuperscript{3}Department of Pharmacology, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju 54907, \textsuperscript{4}Molecular and Cellular Glycobiology Unit, Department of Biological Sciences, Sung Kyun Kwan University, Suwon 16419, Korea

Activation of peroxisome proliferator-activated receptor γ (PPAR\textgamma) serves as a key factor in the proliferation and invasion of breast cancer cells and is a potential therapeutic target for breast cancer. However, the mechanisms underlying this effect remain largely unknown. Heme oxygenase-1 (HO-1) is induced and over-expressed in various cancers and is associated with features of tumor aggressiveness. Recent studies have shown that HO-1 is a major downstream target of PPAR\textgamma. In this study, we investigated the effects of induction of HO-1 by PPAR\textgamma on TPA-induced MMP-9 expression and cell invasion using MCF-7 breast cancer cells. TPA treatment increased NF-κB/AP-1 DNA binding as well as MMP-9 expression. These effects were significantly blocked by 15d-PGJ\textsubscript{2}, a natural PPAR\textgamma ligand. 15d-PGJ\textsubscript{2} induced HO-1 expression in a dose-dependent manner. Interestingly, HO-1 siRNA significantly attenuated the inhibition of TPA-induced MMP-9 protein expression and cell invasion by 15d-PGJ\textsubscript{2}. These results suggest that 15d-PGJ\textsubscript{2} inhibits TPA-induced MMP-9 expression and invasion of MCF-7 cells by means of a heme oxygenase-1-dependent mechanism. Therefore, PPAR\textgamma/HO-1 signaling-pathway inhibition may be beneficial for prevention and treatment of breast cancer. [BMB Reports 2020; 53(4): 212-217]

INTRODUCTION

Breast cancer is the major cause of cancer death in women worldwide. The high prevalence of breast cancer and the limited options for treatment provide an obvious rationale for discovering new molecular targets that can be pharmacologically modulated. Recent evidence suggests that matrix metalloproteinases (MMPs) may play a role in breast cancer initiation and growth (1-3). Key genes involved in breast cancer metastasis, such as MMP, have been the focus of research into targets for cancer breast treatment. Phorbol esters bind to protein kinase C (PKC) in a way similar to that of its natural ligand, diacylglycerol, and activate the kinase (4, 5). The phorbol ester is 12-O-tetradecanoylphorbol-13-acetate (TPA), also called phorbol-12-myristate-13-acetate (PMA), which is used as a biomedical tool for research. Recently it has been found that TPA activates integrin signaling pathway (6, 7), which may be activated by some carcinogens. PPAR\textgamma is one of nuclear receptor subfamily that includes receptors for thyroid, steroid, and retinoid hormones. PPAR\textgamma from heterodimers with retinoid receptors and these dimers regulate various genes (8). Many recent papers have reported that modulations of PPAR\textgamma control the growth of human cancers, such as breast cancer (9-11). One of the earliest events in the metastasis of cancer cells is expression of the γ isoform of PPAR. Thus, PPAR\textgamma control may have significant promise for breast cancer prevention. Recently, PPAR\textgamma ligands were shown to inhibit the growth of a variety of transformed cells (9, 12, 13); hence signals that modulate PPAR\textgamma activity may serve a primary role in regulating breast cancer metastasis and may be major targets for treatment of breast cancer. Endogeneous 15-Deoxy-Δ12,14-prostaglandin J\textsubscript{2} (15d-PGJ\textsubscript{2}) has been identified as a ligand of PPAR\textgamma. 15d-PGJ\textsubscript{2} inhibited the invasiveness of breast cancer cells by upregulating a tissue inhibitor of MMP-1 (14). A recent study has shown that heme oxygenase-1 (HO-1) overexpression in MCF-7 cells inhibits MMP expression, indicating that HO-1 plays a pivotal role in the
invasion of breast cancer cells (15). These results suggest that PPARγ ligands control invasion and MMP expression of human breast cancer cells by means of HO-1. In the present study, we examined the role of HO-1 in the action of 15d-PGJ2 on the invasion and MMP expression of breast cancer cells.

RESULTS

Effect of 15d-PGJ2 on MMP-9 expression in MCF-7 cells

We treated MCF-7 cells with 15d-PGJ2 (0-5 μM) for 24 h, and toxicity was detected using an MTT assay. Treatment with 15d-PGJ2 did not change MCF-7 cell viability (data not shown). Therefore, we used non-toxic concentrations of 2.5 and 5 μM in the experiments. The range of non-toxic concentrations was applied in all subsequent experiments. Gelatin zymography showed that 15d-PGJ2 suppressed TPA-induced MMP-9 secretion in a dose-dependent manner. Western blotting and real-time PCR revealed that 15d-PGJ2 suppressed TPA-induced MMP-9 expression at both mRNA and protein levels (Fig. 1A and B). The luciferase assay showed that 15d-PGJ2, a known PPARγ agonist, suppressed TPA-induced MMP-9 promoter activity in MCF-7 cells (Fig. 1C). We next examined whether the inhibitory effect of 15d-PGJ2 on MMP-9 expression depended on PPARγ. In MCF-7 cells treated with 15d-PGJ2, inhibition of TPA-induced MMP-9 expression was recovered by the PPARγ antagonist GW9662 (Fig. 1D). These results indicate that the inhibition of TPA-induced MMP-9 expression by 15d-PGJ2 does depend on PPARγ.

Effect of 15d-PGJ2 on TPA-induced activation of NF-κB and AP-1 in MCF-7 cells

To investigate the signaling and transcription factors by which 15d-PGJ2 inhibited MMP-9 expression, we used gelatin zymography (zymo) and Western blotting to evaluate the effects of 15d-PGJ2 on the TPA-induced activation of NF-κB and AP-1. TPA-induced MMP-9 expression was inhibited by NF-κB (Bay 11-7082) and AP-1 (SR 11302) inhibitors in a dose-dependent manner (Fig. 2A and B). Pretreatment with 15d-PGJ2 inhibited the transfer of p50, p65, and p-c-Fos to the nucleus by TPA, and 15d-PGJ2 also inhibited phosphorylation of IKKα/β and IκBα (Fig. 2C). In addition, an EMSA assay showed that treatment with 15d-PGJ2 suppressed TPA-induced NF-κB and AP-1 DNA binding activity (Fig. 2D and E). These results indicate that 15d-PGJ2 inhibits TPA-induced MMP-9 expression by regulating NF-κB/AP-1 activation in MCF-7 cells.

Role of HO-1 on MMP-9 expression and cell invasion inhibition by 15d-PGJ2 in MCF-7 cells

We investigated whether HO-1 plays a role in the inhibition of TPA-induced MMP-9 expression by 15d-PGJ2. Western blotting and real-time PCR revealed that 15d-PGJ2 increased HO-1 expression at both protein and mRNA levels in a dose-depen-
15d-PGJ2 inhibits MMP-9 expression and invasion of breast cancer cell HO-1-dependently
Hye-Yeon Jang, et al.

Fig. 3. 15d-PGJ2 inhibits TPA-induced MMP-9 activation and cell invasion by means of the Nrf2/HO-1 signaling pathway in MCF-7 cells. (A, B) We treated MCF-7 cells with 15d-PGJ2 for 24 h. HO-1 protein expression was analyzed by Western blot. HO-1 mRNA levels were analyzed by RT-PCR using GAPDH mRNA as an internal control. (C) Cells were transfected with HO-1 siRNA, and then treated with 15d-PGJ2 and TPA for 24 h. HO-1 siRNA attenuated the inhibitory effects of 15d-PGJ2. MMP-9 secretion was analyzed by gelatin zymography. (D) Cells were transfected with HO-1 siRNA for 24 h. We carried out matrigel invasion assays on cells treated with TPA and 15d-PGJ2. The data presented as the mean number of migrated cells. Data are presented as means ± SE of three independent experiments. **P < 0.01 vs. control. *P < 0.05 vs. control.

Fig. 4. HO-1 regulation affected PPARγ expression in MCF-7 cells. (A, B) We treated cells with 15d-PGJ2 for 0.5, 1, 2, 3, 4 h, followed by cytosol, and then prepared nuclear extracts. Protein expression was analyzed by Western blot. (C) We treated cells with 15d-PGJ2 in the presence of ZnPP for 4 h and then prepared nuclear extracts. (D, E) Cells were transfected with Nrf2 siRNA and HO-1 siRNA for 24 h, and then treated with 15d-PGJ2 for 4 h and then d nuclear extracts and whole cell lysates were prepared. (F) Cells were transfected with HO-1 siRNA for 24 h, and then treated for 3, 6, 12, and 24 h with 15d-PGJ2. (G) Cells were transfected with Nrf2 siRNA and HO-1 siRNA for 24 h. We analyzed PPARγ mRNA levels by real-time PCR using GAPDH mRNA as an internal control. Data are presented as means ± SE of three independent experiments. **P < 0.01 vs. control. *P < 0.05 vs. control.

Effect of HO-1 in 15d-PGJ2-induced PPARγ expression
15d-PGJ2 is known as a PPARγ agonist. We investigated whether HO-1 is involved in PPARγ expression induced by 15d-PGJ2. When cells were treated with 15d-PGJ2 at 0.5, 1, 2, 3, and 4 h, 15d-PGJ2 induced time-dependent PPARγ nuclear translocation (Fig. 4A). In addition, 15d-PGJ2 induced Nrf2 nuclear translocation, a major transcription factor for HO-1 expression (Fig. 4B). The pretreatment with ZnPP, an HO-1 inhibitor, inhibited the increased expression of PPARγ by 15d-PGJ2 (Fig. 4C). To confirm this more clearly, when the cells were transfected with Nrf2 siRNA and HO-1 siRNA for 24 h, Western blotting showed that the increased PPARγ expression by 15d-PGJ2 was inhibited by Nrf2 and HO-1 knockdown (Fig. 4D and E). When cells were treated with 15d-PGJ2 for 3, 6, 12, and 24 h, HO-1 siRNA also inhibited 15d-PGJ2-induced PPARγ mRNA levels (Fig. 4F). Inhibition of Nrf2 and HO-1 also decreased PPARγ mRNA levels (Fig. 4G). These results suggest that PPARγ expression depends on the activation of Nrf2 and HO-1.

DISCUSSION
Activation of peroxisome proliferator activated receptor γ (PPARγ) during carcinogenesis is known to increase as part of normal physiological metabolic factors that affect growth and survival of cancer cells. Furthermore, the potential effect of
PPARγ expression on patient survival has been the focus of breast cancer treatment strategies, suggesting the importance of PPARγ regulation in breast cancer treatment. In this study, we evaluated the relationship between physiologic activation of PPARγ and MMP expression and invasion of breast cancer cells. Thus, we focused on the role of HO-1 in PPARγ activation in the carcinogenesis of breast cancer. Our results showed that 15-Deoxy-A12,14-prostaglandin J2 (15d-PGJ2), an endogenous PPARγ ligand, blocks TPA-induced MMP-9 expression and cell invasion by means of an HO-1-mediated PPARγ signaling mechanism in MCF-7 cells. This suggests that HO-1 may be a novel member of the PPARγ signaling cascade to target for prevention and treatment of breast cancer.

The promoter region of the matrix metalloproteinase-9 (MMP-9) gene has binding sites for nuclear factor-kappa B (NF-kB) and activator protein-1 (AP-1), and TPA is known to induce MMP-9 by means of NF-kB and AP-1 signaling (16, 17). We confirmed that TPA-induced MMP-9 was inhibited by treatment with NF-kB inhibitor BAY11-7082 and AP-1 inhibitor SR11302, and that 15d-PGJ2 inhibits TPA-induced NF-kB signal proteins and p-c-fos (AP-1 subunit). 15d-PGJ2 also inhibited the TPA-induced NF-kB and AP-1 promoter activities. These results indicate that 15d-PGJ2 inhibits MMP-9 by means of TPA-induced NF-kB/AP-1 signal inhibition.

Heme oxygenase (HO) is a rate-limiting enzyme in the degradation of heme. Three HO isoforms have been identified. HO-2 and HO-3 are constitutively expressed, whereas HO-1 is a potent antioxidant enzyme induced by a variety of factors, such as heme and oxidants (18). HO-1 is associated with pathogenesis in human diseases (19). In breast cancer cells, HO-1 inhibit proliferation and induces apoptosis in human cancer cells (20, 21). Although HO-1 has been studied in various cancer cells, the roles of HO-1 in breast cancer cells are still undefined. Here we found that 15d-PGJ2 inhibited MMP-9 expression by 15d-PGJ2-PPARγ signaling cascade. We confirmed that 15d-PGJ2 increased HO-1 expression at both protein and mRNA levels in a dose-dependent manner, and that 15d-PGJ2 inhibitory effects on TPA-induced MMP-9 expression were significantly decreased in transfectected with Nrf2 siRNA and HO-1 siRNA, the increased PPARγ expression by 15d-PGJ2 was inhibited by Nrf2 and HO-1 knockdown. Inhibition of Nrf2 and HO-1 also decreased PPARγ mRNA levels. These results indicate that PPARγ expression depends on the activation of Nrf2 and HO-1 in MCF-7 cells. Collectively, these findings suggest that HO-1 is a major regulator of PPARγ expression in the pathogenesis of breast cancer.

In conclusion, this study demonstrates that MMP-9 expression and invasion of ER-positive breast cancer cells may be regulated by means of an HO-1-induced PPARγ signaling mechanism. Our data showed that HO-1 may be a novel target in the PPARγ signaling cascade for prevention and treatment of breast cancer. However, additional experiments are necessary to confirm this relationship between HO-1 and PPARγ at the transcription factor level and to further delineate its molecular basis.

MATERIALS AND METHODS

Cells and materials
We purchased:
- MCF-7 cells from the American Type Culture Collection (ATCC, Manassas, VA, USA); these were cultured at 37°C in a 5% CO2 incubator in DMEM (Gibco, Gaithersburg, MD, USA) with 1% antibiotics and 10% FBS (Gibco).
- 15d-PGJ2 from Cayman Chemical (Ann Arbor, MI, USA).
- Anti-p-actin antibody, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and 12-O-tetradecanoylphorbol-13-acetate (TPA) from Sigma-Aldrich (St Louis, MO, USA).
- Primary antibodies to p-c-Fos, p-IκBα, and p-IκKα/β from Cell Signaling Technology (Danvers, MA, USA).
- MMP-9, p65, p50, PPARγ, Nrf2, PCNA antibodies, NF-κB inhibitor BAY 11-7082, and AP-1 inhibitor SR 11302 from Santa Cruz Biotechnology (Dallas, TX, USA).
- Heme oxygenase-1 (HO-1) antibody and PPARγ inhibitor GW9662 from Enzo Life Sciences (New York, NY, USA).
- NF-κB and AP-1 consensus oligonucleotides from Promega (Fitchburg, WI, USA).

Cell viability
We confirmed the effect of 15d-PGJ2 on cell viability of MCF-7 using an MTT assay. Cells were seeded in each well of 96-well plates at a density of 3 × 10^4 cells/well. After 24 h, cells were stimulated with 2.5, 5, 10, or 20 μM 15d-PGJ2 for 24 h at 37°C. The cells were then washed with PBS, and MTT (0.5 mg/ml of PBS) was added; we then incubated the treated cells at 37°C for 30 min. We dissolved Formazan crystals with DMSO. OD was detected at 570 nm using a microplate reader (Bio-Rad, Richmond, CA, USA).

Preparation of nuclear extract
We treated MCF-7 cells with 15d-PGJ2 in the presence or absence of TPA (100 nM) for 3 h. Cells were washed twice, scraped into 1.5 ml of PBS, and pelleted at 4,000 × g for 4
min. We prepared cytoplasmic and nuclear extracts using NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Waltham, MA, USA).

**Western blot analysis**
We pretreated MCF-7 cells with 15d-PGJ$_2$ for 1 h and then incubated them with TPA for 24 h at 37°C. Cells were lysed using M-PER Mammalian Protein Extraction Reagent (Thermo Fisher). We separated samples (10 μg) by SDS-PAGE gels, and the protein loaded-gel were transferred to Hybond-polyvinylidene fluoride membranes (GE Healthcare Life Sciences, Pittsburgh, PA, USA) for 1 h. Each membrane was blocked for 2 h with 5% skim milk or 5% bovine serum albumin and was then incubated with a primary antibody overnight at 4°C. We detected protein levels with an image analyzer (Fuji-Film, Tokyo, Japan). We did densitometry using Image J software (NIH, Bethesda, MD, USA).

**Gelatin zymography assay**
We pretreated cells with 15d-PGJ$_2$, BAY 11-7082, and SR 11302 for 1 h and then incubated them with TPA for 24 h at 37°C. After that, we collected conditioned media and separated them in a polyacrylamide gel containing 0.1% (w/v) gelatin. The gel was washed with 2.5% Triton X-100, incubated at 37°C for 15 h in developing buffer, subsequently stained with 0.25% (w/v) Coomassie blue buffer and photographed on an image analyzer (Fuji-Film).

**Quantitative real-time polymerase chain reaction**
Total RNA was extracted from cells using RNAiso Plus (Takara, Shiga, Japan). We detected the RNA purity and concentration by absorbance at 260/280 nm. We synthesized cDNA using a PrimeScript RT reagent Kit (Takara), GAPDH (NM002046), PPAR (NM 001330615), HO-1 (NM 002133), and MMP-9 (NM 004994) mRNA expression was detected by real-time PCR using a SYBR Green and ABI PRISM 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA).

**Luciferase assay**
MCF-7 cells were seeded on 24-well plates until the cells reached 60-70% confluence and were then transfected with MMP-9 reporter plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). We pretreated the transfected cells with 15d-PGJ$_2$ for 1 h and then incubated them with TPA for 24 h. We did luciferase reporter assays using the Dual-Luciferase Reporter Assay System (Promega) and detected them using a luminometer (EG & G Berthold, Gaithersburg, MD, USA). We did statistical analysis using ANOVA and Duncan’s test. Differences with P < 0.05 were considered statistically significant.

**ACKNOWLEDGEMENTS**
This paper was supported by the Fund of Biomedical Research Institute, Chonbuk National University Hospital and National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2016R1D1A1B03930499).

**CONFLICTS OF INTEREST**
The authors have no conflicting interests.

**REFERENCES**
1. Jablonska-Trypuc A, Matejczyk M and Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzy Inhi Med Chem 31, 177-
15d-PGJ2 inhibits MMP-9 expression and invasion of breast cancer cell HO-1-dependently
Hye-Yeon Jang, et al.

2. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ and Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10, 7621-7628
3. Kohmann A, Karmenrue U, Kapp M, Dietl J and Anacker J (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9, 188
4. Ono Y, Fujii T, Igarashi K et al (1989) Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc Natl Acad Sci U S A 86, 4868-4871
5. Gould CM and Newton AC (2008) The life and death of protein kinase C. Curr Drug Targets 9, 614-625
6. Su Z, Song J, Wang Z et al (2018) Tumor promoter TPA activates Wnt/beta-catenin signaling in a casein kinase 1-dependent manner. Proc Natl Acad Sci U S A 115, E7522-E7531
7. Kim HJ, Park SY, Park OJ and Kim YM (2013) Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Mol Med Rep 8, 282-286
8. Diradourian C, Girard J and Pegorier JP (2005) Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87, 33-38
9. Wang X, Sun Y, Wong J and Conklin DS (2013) PPARgamma maintains ERBB2-positive breast cancer stem cells. Oncogene 32, 5512-5521
10. Robbins GT and Nie D (2012) PPAR gamma, bioactive lipids, and cancer progression. Front Biosci (Landmark Ed) 17, 1816-1834
11. Kourtidis A, Srinivasiah R, Carkner RD, Brosnan MJ and Conklin DS (2009) Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 11, R16
12. Srivastava N, Kollipara RK, Singh DK et al (2014) Inhibition of cancer cell proliferation by PPARgamma is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metab 20, 650-661
13. Tsubaki M, Takeda T, Tomonari Y et al (2018) Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AlF expression via a PPARgamma-independent pathway. J Cell Physiol 233, 3638-3647
14. Liu H, Zang C, Fenner MH, Possinger K and Elstner E (2003) PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 79, 63-74
15. Lin CW, Shen SC, Hou WC, Yang LY and Chen YC (2008) Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol Cancer Ther 7, 1195-1206
16. Yokoo T and Kitamura M (1996) Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol 270, F123-130
17. Park JH, Jeong YJ, Park KK et al (2010) Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells 29, 209-215
18. Maines MD (1988) Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2, 2557-2568
19. Wu ML, Ho YC, Lin CY and Yet SF (2011) Heme oxygenase-1 in inflammation and cardiovascular disease. Am J Cardiovasc Dis 1, 150-158
20. Lee HN, Jin HO, Park JA et al (2015) Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine. Mol Cells 38, 327-335
21. Lee WY, Chen YC, Shih CM et al (2014) The induction of heme oxygenase-1 suppresses heat shock protein 90 and the proliferation of human breast cancer cells through its byproduct carbon monoxide. Toxicol Appl Pharmacol 274, 55-62
22. Kronke G, Kadl A, Ikonomou E et al (2007) Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 27, 1276-1282
23. Park SY, Bae JU, Hong KW and Kim CD (2011) HO-1 Induced by cilostazol protects against TNF-alpha-associated cytotoxicity via a PPAR-gamma-dependent pathway in human endothelial cells. Korean J Physiol Pharmacol 15, 83-88
24. Vanella L, Kim DH, Asprinio D et al (2010) HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone 46, 236-243